Key result
Structured patient blood management improves outcomes in surgical patients with anemia.
Why the study?
Anaemia is common in surgical patients and associated with increased morbidity and mortality, yet preoperative assessment often leaves little time to manage it.
A structured 5-step checklist for perioperative patient blood management can help surgeons systematically address anemia, manage bleeding, and optimize transfusion practices to improve patient outcomes.
Answers are grounded in this paper and cite their sources.
Supports adoption of patient blood management in surgical anaemia; reinforces evidence for intravenous iron and restrictive transfusion.
Anaemia is a common problem in surgical patients1. In a pivotal review of 227 425 patients in the US NSQIP database, 30% had preoperative anaemia which was associated with increased 30-day morbidity (adjusted OR 1.35 (95% c.i. 1.30 to 1.40)), and mortality (OR 1.42 (95% c.i. 1.31 to 1.54)) rates, presenting a similar and additive risk to cardiac disease or diabetes1. After surgery, most patients are anaemic and those discharged home with a haemoglobin (Hb) < 100 g/l had higher rates of readmission and worsening frailty during recovery2. There are several opportunities for the surgeon to address anaemia in their patients, and clinical trials have highlighted numerous interventions which have improved patient outcomes. Patient blood management (PBM) has become an established programme of care involving the treatment of anaemia, management of bleeding, and appropriate use of blood transfusion3. As a surgeon, this practically translates into: identifying preoperative anaemia; perioperative management of antiplatelets and anticoagulants; use of tranexamic acid during surgery; careful decision-making with respect to blood transfusion and blood products; and postoperative management of anaemia. These issues would be well suited for intervention directed from the surgical multidisciplinary team (MDT), well before preoperative assessment. Preoperative assessment is often undertaken very close to surgery, with scheduling and other logistical aspects often taking priority, leaving little time to manage preoperative anaemia. Yet surgical pathways for investigation, diagnosis, staging, and MDT precede this and therefore an Hb < 130 g/l noted at this stage should trigger further investigation and management of anaemia in a similar way to other common co-morbidities such as cardiac disease or diabetes4. Globally, the commonest cause of anaemia is iron deficiency either due to nutritional deficiency or blood loss leading to a state of absolute iron deficiency (AID), diagnosed by ferritin <30 µg/l. Additionally, inflammation or chronic disease can elevate the iron regulatory protein, hepcidin, which leads to sequestering of available iron with reduced iron absorption and transport (Fig. 1). Termed functional iron deficiency, this is manifest by elevated ferritin but low transferrin saturations (a calculation of serum iron/total iron binding capacity <20%)5,6. B12 and folate deficiency is present in approximately 5–10% of patients7. The effect of hepcidin on iron metabolism National Institute for Health and Care Excellence (NICE) guideline NG24 advises the first line treatment of iron deficiency (ferritin < 30 µg/l) as oral iron tablets in the preparations of iron sulphate/gluconate/fumarate or bisglycinate; most doses are 200–300 mg per tablet (containing 45–100 mg of elemental iron).8 There is no difference between the preparations and recommendations are one tablet per day, with higher doses merely increasing hepcidin and reducing absorption. Alternate day dosing may reduce side effects and be comparably effective. Overall, net iron absorption is about 200–250 mg per month, and therefore 3–6 months of treatment is often required. In the setting of imminent surgery this may not be logistically feasible; however, intravenous iron administration bypasses this problem5. Modern intravenous iron (Ferinject or Monofer) enables a large treatment of 1000–1600 mg to be given in 30 min with similar side-effect profiles to other infusions, for example intravenous contrast or an antibiotic. To assess the role of intravenous iron in patients with preoperative anaemia before major open abdominal surgery, the PREVENTT RCT investigated 487 patients at multiple UK sites in a double-blind, placebo-controlled study. Surprisingly, the primary analysis showed no difference in blood transfusion rates, complications, or patient outcomes; however, the effect of intravenous iron was greatest after surgery increasing Hb levels after discharge (mean difference 10.7 g/l (95% c.i. 7.8 to 13.7)) and reducing readmissions for surgical complications (22% versus 13%, risk ratio 0.61 (95% c.i. 0.40 to 0.91)). Together, the current RCT data suggest that intravenous iron has the greatest effect in those undergoing colorectal surgery and in all patients with ferritin < 30 µg/l. It is not uncommon for surgical patients to be on antiplatelet or anticoagulant therapy and there is often individual patient discussion regarding the safety of stopping this treatment, the need for ‘bridging therapy’, and when to recommence therapy after surgery. The POISE 2 trial randomized over 10 000 patients at increased cardiovascular risk prior to major surgery to receive either aspirin or placebo9. There was no difference in the primary outcome, a composite of death or non-fatal myocardial infarction at 30 days (7% versus 7.1%), but a higher rate of major bleeding was seen in the aspirin group (4.6% versus 3.8%; HR 1.23 (95% c.i. 1.01 to 1.49), P = 0.04). Withdrawal of aspirin for 10 days is required to eliminate the antiplatelet effect, and for patients on clopidogrel this is a relative contraindication for spinal/epidural anaesthesia. The BRIDGE study, which randomized 1884 patients with atrial fibrillation (AF) to receive bridging low-molecular-weight heparin or placebo, reported that avoiding bridging in patients with AF who temporarily stop warfarin for surgery did not increase thromboembolism but did significantly reduce major bleeding10. Indeed, the only patients at higher risk were those with AF and a mechanical heart valve. Current recommendations for direct oral anticoagulant (DOAC) therapy are to cease treatment 48 h prior to major and 24 h prior to minor surgery. A pivotal message from the BRIDGE study was that anticoagulation could safely be restarted on the evening of or the day after the procedure, with no reason to delay recommencement of a DOAC (or treatment dose low-molecular-weight heparin) in stable postoperative patients. This is important in the era of electronic patient records, where clarity is needed to ensure ward staff follow the intended treatment pathway. Tranexamic acid (TXA) is an amino acid, and as a synthetic analogue of lysine it works to prevent tissue plasminogen activator from binding to fibrinogen and so prevents clot lysis. This mechanism of action does not in itself cause clots (Fig. 2). The effect of tranexamic acid (TXA) on plasminogen and fibrin degradation on clot stabilization FBC, full blood count; GI, gastrointestinal; TSAT, transferrin saturation. In the POISE 3 trial, an RCT of more than 9500 patients comparing TXA with placebo in non-cardiac surgery (including vascular surgery), TXA was found to significantly reduce bleeding11. The most recent systematic review of the use of TXA included 26 randomized trials incorporating over 6900 patients and demonstrated that TXA reduced blood loss, reduced requirement for transfusion, and reduced major bleeding in general surgery without increasing thromboembolic events or mortality rate12. In these patients, and all those at risk of bleeding, TXA 1 g IV should be given at induction as part of the surgical WHO checklist. In elective orthopaedic surgery, 1 g orally 1 h preoperatively appears to be as effective. In the last decade there have been multiple trials in all areas of medicine and surgery that have confirmed no benefit of ‘top up’ blood transfusions. In total, 61 trials (27 639 participants) across a range of clinical contexts confirmed that restrictive transfusion (70–80 g/l) saved blood and did not modify the 30-day mortality rate compared with liberal transfusion strategies (RR 1.01 (95% c.i. 0.90 to 1.14))13. Transfusion carries several risks, ranging from minor (febrile reactions) to anaphylaxis, lung injury, circulatory overload, infection, and death. A single unit strategy that abides by the above restrictive thresholds has been recommended by NICE to minimize transfusion risks8. However, the practice of restrictive transfusion does increase the proportion of patients who are anaemic following surgery with an inherent need to focus attention on how to improve their recovery. The POSTVENTT study, involving 5266 patients across 101 centres, reported that patients with postoperative anaemia were more likely to be readmitted within 30 days (9.5% versus 5.5%, P < 0.001). This was more significant in those with Hb < 100 g/l (HR 2.08 (95% c.i. 1.46 to 2.96), P < 0.001)2. The study also reported worsening frailty at 30 days in those with anaemia. One thing that is clear from all six RCTs is that oral iron replacement was ineffective with no benefits seen in the postoperative period. This is likely due to ongoing inflammation that can take several weeks to resolve (Fig. 1), and therefore prescription of oral iron in this scenario should be avoided. Conversely, high-dose IV iron supplementation can increase haemoglobin concentration, supporting the findings of both PREVENTT and FIT studies14–16. It is therefore logical that in patients with significant blood loss at surgery, or in those with moderate/severe anaemia (Hb < 100 g/l), that 500–1600 mg of IV iron is administered in the postoperative period. This treatment approach is simple, cheaper than blood, and logistically straightforward to administer either in recovery or on the surgical ward. As 1 litre of blood requires 500 mg of iron to replenish, this will enable patients to rebuild blood stocks and recover from anaemia, with contemporary data suggesting that this will improve recovery and reduce complications requiring hospital readmission. We propose a 5 step checklist for surgeons (Fig. 3) to manage anaemia, bleeding and blood transfusion that can become a protocol at MDT and through the patient journey. An investigation and treatment flowchart summarizing the key points for the management of anaemia in surgery Sandaruwani Abeysiri (Writing—original draft, Writing—review & editing), Sashini Iddawela (Writing—review & editing), and Toby Richards (Conceptualization, Supervision, Writing—review & editing) The authors have no funding to declare. S.A. and S.I. have no conflicts to declare. T.R.—no conflicts in the preparation of this manuscript.
No takes yet. Share an insight, caveat, or question.
Abeysiri et al. (2026) conducted a review in Perioperative anaemia. Patient blood management (PBM) was evaluated. Patient blood management, including preoperative intravenous iron, tranexamic acid, and restrictive transfusion, provides a structured approach to improving outcomes in surgical patients with anaemia.
Synapse has enriched 10 related papers. Consider them for comparative context: